Expression of cysteinyl leukotriene receptor 1 and 2 (CysLTR1 and CysLTR2) in the lymphocytes of hyperplastic tonsils: comparison between allergic and nonallergic snoring children

Paulucci, Bruno; Pereira, Juliana; Picciarelli, Patrícia; Levy, Débora; Francesco, Renata Cantisani Di

doi:10.1002/alr.21798

Cited by 8 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial open-labeled study examining a potential role for anti-leukotriene therapy in pediatric OSA showed encouraging evidence that improvements in both the severity of respiratory disturbance and in the adenoid size could be anticipated in a large proportion of children with mild OSA [60]. We subsequently identified the presence of increased expression and activity of cysteinyl leukotriene receptors within lymphadenoid tissues of OSA children, and these could even be detected in exhaled condensate, serum, circulating white blood cells, or in urine [61][62][63][64][65][66][67][68][69][70]. Two RCTs have been conducted to date and have shown the favorable response to montelukast as a single agent in the treatment of pediatric OSA [71,72].…”

Section: Montelukastmentioning

confidence: 99%

Treatment of Obstructive Sleep Apnea in Children: Handling the Unknown with Precision

Gozal

Tan

Kheirandish‐Gozal

2020

JCM

View full text Add to dashboard Cite

Treatment approaches to pediatric obstructive sleep apnea (OSA) have remarkably evolved over the last two decades. From an a priori assumption that surgical removal of enlarged upper airway lymphadenoid tissues (T&A) was curative in the vast majority of patients as the recommended first-line treatment for pediatric OSA, residual respiratory abnormalities are frequent. Children likely to manifest persistent OSA after T&A include those with severe OSA, obese or older children, those with concurrent asthma or allergic rhinitis, children with predisposing oropharyngeal or maxillomandibular factors, and patients with underlying medical conditions. Furthermore, selection anti-inflammatory therapy or orthodontic interventions may be preferable in milder cases. The treatment options for residual OSA after T&A encompass a large spectrum of approaches, which may be complementary, and clearly require multidisciplinary cooperation. Among these, continuous positive airway pressure (CPAP), combined anti-inflammatory agents, rapid maxillary expansion, and myofunctional therapy are all part of the armamentarium, albeit with currently low-grade evidence supporting their efficacy. In this context, there is urgent need for prospective evidence that will readily identify the correct candidate for a specific intervention, and thus enable some degree of scientifically based precision in the current one approach fits all model of pediatric OSA medical care.

show abstract

Section: Montelukastmentioning

confidence: 99%

Treatment of Obstructive Sleep Apnea in Children: Handling the Unknown with Precision

Gozal

Tan

Kheirandish‐Gozal

2020

JCM

View full text Add to dashboard Cite

show abstract

“…They are also systemically and locally involved in the process of inflammation in AH [11] . Studies have confirmed the overexpression of CysLTR1 [12] and CysLTR2 [13] in the adenoid tissue. Also, treatment with leukotriene receptor antagonist has been shown to reduce the adenoid volume [14] .…”

Section: Discussionmentioning

confidence: 72%

Novel Classification System Of Adenoids Based On Appearance And Its Relationship With Drug Therapy

Chang

Dang

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: To investigate the appropriate drug therapy based on a novel classification system for adenoids based on their appearance. Methods: We used fiberoptic nasal endoscopy to determine the degree and appearance of adenoid hypertrophy (AH). The adenoids were divided into three types: edematous type, common type, and fibrous type. In adenoid tissues, the eosinophils were counted. Immunohistochemistry and western blot were done to determine the expression of CysLTR1, CysLTR2, CGR-α, and CGR-β in different types of adenoids. Results: 70.67% (106/150) AH patients with AR, and of them 68% (72/106) of adenoids were the edematous type. The expression of CGR-α and CGR-β and eosinophil count were higher in the edematous type but not in common and fibrous types. The expression of the leukotriene receptor was stable in all types. There was a positive correlation between eosinophil count in the blood and in the adenoid tissue. Conclusion: AR was the risk factor for the development of AH. Leukotriene receptor antagonist was an important drug for the treatment of AH. The glucocorticoid was only useful in the edematous type. Therefore, for AH patients with AR, patients with edematous type adenoids and/or patients with increased eosinophils in blood routine choose nasal glucocorticoid combined with leukotriene receptor antagonist is appropriate. On the contrary, leukotriene receptor antagonists alone can be selected to treat AH.

show abstract

“…Those data suggest that the activation of p-ERK1/2 is involved in the progression of adenoid hypertrophy. It has been reported that the biological functions of CYSLTR1 in allergic responses is closely related to the activation of ERK1/2 signaling pathway (16). In the present study, HAECs with CYSLTR1 overexpression and knockdown were constructed to investigate the interactions between CYSLTR1 and ERK1/2.…”

Section: Discussionmentioning

confidence: 95%

CYSLTR1 promotes adenoid hypertrophy by activating ERK1/2

Gao

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Cysteinyl leukotriene receptor 1 (CYSLTR1) serves a pivotal role in allergic reactions, which is one of the main causes of adenoid hypertrophy. The present study aimed to investigate the function of CYSLT1 within adenoid hypertrophy. A total of 40 patients with adenoid hypertrophy were recruited between January 2014 and January 2016 at the Children's Hospital of Hebei Province, China. The patients were divided into either the mild-moderate group or the severe group according to their disease severity. The expression of CYSLT1 in the adenoid tissue and whole blood of all patients and healthy controls was detected by reverse transcription-quantitative polymerase chain reaction. Associations between the expression level of CYSLT1 and the clinical characteristics of patients were analyzed. Primary human adenoid epithelial cells (HAECs) with CYSLT1 knockdown and overexpression were constructed. The levels of extracellular signal-regulated kinase (ERK)2 and phosphorylated-ERK1/2 in adenoid tissue and HAECs were detected by western blot analysis. The expression of CYSLT1 in adenoid tissue and whole blood of all patients with adenoid hypertrophy was significantly higher compared with the healthy controls (P<0.05). In addition, the expression level of CYSLT1 was significantly higher in the severe group compared with the mild-moderate group (P<0.05). The highest level of p-ERK1/2 in adenoid tissue was observed in the severe group, followed by the mild-moderate group and then the control group (P<0.05). CYSLT1 expression was positively associated with the severity of disease. CYSLT1 knockdown significantly decreased the level of p-ERK1/2 in HAECs (P<0.05), while CYSLT1 overexpression significantly increased the level of p-ERK1/2. It was concluded that CYSLT1 may contribute to the progression of adenoid hypertrophy by activating ERK1/2.

show abstract

Expression of cysteinyl leukotriene receptor 1 and 2 (CysLTR1 and CysLTR2) in the lymphocytes of hyperplastic tonsils: comparison between allergic and nonallergic snoring children

Abstract: The expression of CysLTR is higher in the lymphocytes of the NS children, and CysLTR2 shows greater expression than CysLTR1 Respiratory allergies do not appear to be a stimulus for AH occurrence. Newer drugs capable of blocking both CysLTRs warrant further study.

Cited by 8 publications

References 41 publications

Treatment of Obstructive Sleep Apnea in Children: Handling the Unknown with Precision

Treatment of Obstructive Sleep Apnea in Children: Handling the Unknown with Precision

Novel Classification System Of Adenoids Based On Appearance And Its Relationship With Drug Therapy

CYSLTR1 promotes adenoid hypertrophy by activating ERK1/2

Contact Info

Product

Resources

About